Sorafenib tosylate novel drug delivery systems: Implications of nanotechnology in both approved and unapproved indications

Abstract

The USFDA has approved sorafenib tosylate for the treatment of thyroid cancer, kidney cancer, and hepatocellular carcinoma. Conventional formulations of sorafenib tosylate have challenges of solubility, permeability, side effects, and drug resistance across cancer cells. Targeted cancer therapies based on nanotechnology have proven to be effective and have the potential to become a useful tool in these approved cancer indications. In addition, Sorafenib tosylate's novel formulations are also being investigated for the unapproved indications like hepatocellular cancer, renal cancer, and cholangiocarcinoma with promising outcomes. Nanotechnology-based formulations have shown considerable gains in bioavailability, absorption, and increased anticancer efficacy. The article reviews some of the relevant patents and clinical trials in this field. The article also assesses challenges associated and future prospects in designing such clinical ready novel formulations of sorafenib tosylate.

Keywords

• Sorafenib Tosylate
• Hepatocellular cancer
• Renal cancer
• Differentiated thyroid Cancer
• Nano drug delivery system
• Co-delivery